Aarti Drugs Ltd
NSE:AARTIDRUGS

Watchlist Manager
Aarti Drugs Ltd Logo
Aarti Drugs Ltd
NSE:AARTIDRUGS
Watchlist
Price: 397.75 INR -1.79% Market Closed
Market Cap: 36.3B INR

Relative Value

The Relative Value of one AARTIDRUGS stock under the Base Case scenario is 783.38 INR. Compared to the current market price of 397.75 INR, Aarti Drugs Ltd is Undervalued by 49%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AARTIDRUGS Relative Value
Base Case
783.38 INR
Undervaluation 49%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
64
Median 3Y
1.7
Median 5Y
1.8
Industry
2.6
Forward
1.5
vs History
98
vs Industry
23
Median 3Y
24.5
Median 5Y
23.7
Industry
21.7
Forward
13.8
vs History
58
vs Industry
37
Median 3Y
15.7
Median 5Y
19.5
Industry
16.6
vs History
vs Industry
14
Median 3Y
54.1
Median 5Y
54.1
Industry
22.5
vs History
95
vs Industry
30
Median 3Y
3.4
Median 5Y
3.8
Industry
2.3
vs History
87
vs Industry
62
Median 3Y
1.8
Median 5Y
1.9
Industry
2.9
Forward
1.6
vs History
96
vs Industry
47
Median 3Y
5.6
Median 5Y
6.1
Industry
5.5
vs History
92
vs Industry
29
Median 3Y
14.7
Median 5Y
14.9
Industry
13.1
Forward
8.5
vs History
92
vs Industry
28
Median 3Y
17.7
Median 5Y
17.6
Industry
16.6
Forward
13.8
vs History
58
vs Industry
36
Median 3Y
16.3
Median 5Y
20.6
Industry
15.8
vs History
23
vs Industry
15
Median 3Y
39.1
Median 5Y
39.1
Industry
19.1
vs History
92
vs Industry
39
Median 3Y
2.3
Median 5Y
2.5
Industry
1.9

Multiples Across Competitors

AARTIDRUGS Competitors Multiples
Aarti Drugs Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Aarti Drugs Ltd
NSE:AARTIDRUGS
36.4B INR 1.5 18.2 12.4 15.3
US
Eli Lilly and Co
NYSE:LLY
955.6B USD 16.1 51.9 34.9 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.9B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
251.9B CHF 4.1 26.7 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
211.7B GBP 4.9 30 108.3 158.5
CH
Novartis AG
SIX:NOVN
206.7B CHF 4.6 17.9 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
248B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.3 13 9.1 10.6
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
IN
Aarti Drugs Ltd
NSE:AARTIDRUGS
Average P/E: 22.8
18.2
24%
0.8
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.7
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
38%
0.8
CH
Novartis AG
SIX:NOVN
17.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Aarti Drugs Ltd
NSE:AARTIDRUGS
Average EV/EBITDA: 398.9
12.4
22%
0.6
US
Eli Lilly and Co
NYSE:LLY
34.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Aarti Drugs Ltd
NSE:AARTIDRUGS
Average EV/EBIT: 1 709
15.3
25%
0.6
US
Eli Lilly and Co
NYSE:LLY
37.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
1%
10.6
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3